QPS Forms Strategic Alliance with Taiwan's Development Center for Biotechnology

NEWARK, Del.--(Business Wire)--
QPS, a leading full-service GLP-compliant contract research organization
providing testing services to support preclinical and clinical research and
development, announced today its strategic alliance with Taiwan`s Development
Center for Biotechnology (DCB). DCB is a non-profit organization supported
primarily by government funding to advance Taiwan biotech industry and serve as
a bridge between Taiwan and the rest of the world.

This strategic alliance leverages the strengths of both organizations and gives
biopharmaceutical companies access to a complete range of drug development
services from preclinical through clinical services. In conjunction with DCB,
QPS` current services will be expanded into chemistry, manufacturing and
controls (CMC), in vitro/in vivo toxicology, and pharmacology. It is noteworthy
that the recently passed Taiwan Biotechnology Takeoff Package has also paved the
way for the expansion of DCB`s services to cover process development and cGMP
production of biopharmaceuticals.

"QPS currently operates a state-of-the-art, bioanalytical LC/MS/MS facility in
Taipei, Taiwan. Our partnership with DCB provides QPS with access to enhanced
service offerings, not only to our clients in the Asia-Pacific Rim region, but
around the world," stated QPS CEO and Founder, Ben Chien, Ph.D. "We now have the
ability to expand our services to cover preclinical through clinical with even
more efficiencies of scale-to increase speed and reduce costs while maintaining
our focus on accuracy of data. As with QPS, the DCB has a strong history and
reputation with providing valuable and accurate services."

"DCB now positions itself as a "preclinical value-adding R&D center for
biopharmaceuticals" in Taiwan`s drug development value-chain. Our organization
has been collaborating with QPS on a project-by-project basis. The new strategic
alliance with QPS will not only provide complete and integrated
international-standard preclinical testing services to domestic and
pharmaceutical companies, but also lead to new clients and expanded business
opportunities for DCB in the international drug development arena. We believe
this will bring us one step closer to realizing our vision of becoming an
internationally outstanding preclinical research and service institute for
biopharmaceutical development," stated DCB President, Dr. Chia-Lin Jeff Wang.

About QPS
QPS provides GLP/GCP-compliant preclinical and clinical research services to
pharmaceutical and biotechnology clients worldwide in the areas of bioanalysis,
preclinical DMPK, translational medicine research, and early-phase clinical
research. Our regional laboratories are located at Newark, Delaware;
Springfield, Missouri; and Taipei, Taiwan. www.qps-usa.com.

About Development Center for Biotechnology
The Development Center for Biotechnology (DCB) of Taiwan is a non-profit
organization established in 1984 with the support of the Department of
Industrial Technology (DOIT), Ministry of Economic Affairs (MOEA). Our main
mission is to help shape and develop Taiwan`s biotechnology industry through
R&D, infrastructure-building and training programs. www.dcb.org.tw.

QPS
Zamas Lam, 302-369-5117
Executive Director of Strategic Planning and Marketing
Zamas.lam@qps-usa.com
or
The Development Center for Biotechnology (DCB) of Taiwan
Kenneth Wang, +886.987.214.611
Manager of Public Affairs, DCB, Taiwan
Kenneth@mail.dcb.org.tw

Copyright Business Wire 2009